1. India Stocks

  2. •

    Health technology

  3. •

    Pharmaceuticals: major
Indoco Remedies Limited

Indoco Remedies Limited

225.50
INR
-7.85
(-3.36%)
0.36EPS
369.60P/E
22.03BMarket Cap
Oct 27Next Earn
2014 Y
2015 Y
2016 Y
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
2026 Y
TTM
Revenue per Share
79.5
93
109.4
113.66
110.44
103.81
117.2
132.28
163.18
177.98
194.05
178.02
194.34
209.99
Basic EPS, GAAP
6.29
8.99
8.89
8.36
4.47
-0.32
2.62
10.1
16.8
15.44
10.68
-8
-10.31
0.65
Free Cash Flow per Basic Share
10.72
11.83
12.18
9.62
13.32
14.56
13.33
8.93
18.86
19.41
16.86
9.84
24.53
- -
Dividend per Share
1.29
1.64
3.58
0.26
1.92
1.22
0.36
0.3
1.5
2.25
2.25
1.51
0.21
- -
Book Value per Share
49.61
57.27
62.56
70.68
73.25
71.69
73.75
83.45
98.17
111.58
120.44
110.89
101.9
- -
Tangible Book Value per Share
44.29
48.43
52.99
60.11
61.58
61.36
63.82
74.27
88.19
98.1
100.04
90.03
80.1
- -
Basic Weighted Avg Shares
92
92
92
92
92
91
92
92
92
92
92
92
92
87
Sales/Revenue/Turnover
7,326
8,570
10,081
10,474
10,177
9,421
10,800
12,186
15,037
16,400
17,882
16,413
17,929
18,283
Operating Margin (%)
12.36
14.42
11.19
8
6.37
-0.99
4.48
13.06
14.65
12.05
7.99
-0.89
0.86
1.86
Depreciation Expense
309
471
607
633
677
716
708
731
772
706
919
983
1,069
1,313
Net Income, GAAP
580
828
819
771
412
-29
241
930
1,548
1,423
985
-737
-951
56
Effective Tax Rate (%)
19.75
24.4
17.17
15.26
14.95
- -
15.59
29.51
34.57
26.22
28.57
- -
- -
60.66
Profit Margin (%)
7.91
9.66
8.13
7.36
4.04
-0.31
2.23
7.64
10.29
8.67
5.51
-4.49
-5.31
0.31
Working Capital
1,024
1,306
1,616
1,817
1,216
926
1,041
2,156
3,488
3,891
3,423
1,933
1,408
- -
LT Debt
138
128
379
1,323
1,233
1,287
1,024
1,039
1,068
1,585
3,641
5,426
5,584
- -
Total Equity
4,574
5,277
5,765
6,513
6,750
6,606
6,796
7,690
9,046
10,283
11,105
10,184
9,321
- -
Return on Invested Capital (%)
14.03
15.79
13.76
8.49
5.28
- -
3.33
10.17
13.01
11.71
6.77
- -
- -
- -
Return on Capital (%)
12.65
15.36
13.64
10.85
5.87
- -
4.5
10.87
15.07
12.67
7.94
- -
- -
- -
Return on Common Equity (%)
13.31
16.82
14.84
12.55
6.21
-0.43
3.6
12.85
18.5
14.72
9.21
-6.92
-9.7
- -

Capital Structure

INR

•

in mil. unless spec.
Dec'26
Mar'26
Jun'27
ST Debt
- -
5,314
- -
LT Borrowings
- -
5,160
- -
LT Finance Leases
- -
423
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
92
92
92
Market Capitalization
21,639
15,195
22,027

Working Capital

INR

•

in mil. unless spec.
Dec'26
Mar'26
Jun'27
Total Current Assets
- -
11,934
- -
Cash, Cash Equivalents & STI
- -
458
- -
Accounts Receivable, Net
- -
4,892
- -
Inventories
- -
4,052
- -
Total Current Liabilities
- -
10,525
- -
Payables & Accruals
- -
- -
- -
ST Debt
- -
5,314
- -
Deferred Revenue
- -
- -
- -

Growth Rates

INR

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
5.3%
4.51%
-8.47%
Free Cash Flow
19.4%
41.8%
149.39%
Net Income, GAAP
-92.27%
-23.68%
29.03%
Sales/Revenue/Turnover
6.36%
8.5%
9.24%
Total Cash Common Dividend
74.19%
65.13%
-86.26%

Quarterly Revenue

INR

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2025
4,243
4,307
4,025
3,839
16,413
2026
4,309
4,718
4,343
4,559
17,929
2027
4,662
- -
- -
- -
- -

Quarterly Earnings Per Share

INR

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2025
0.29
-1.09
-3.08
-4.48
-8
2026
-3.94
-1
-3.2
-2.57
-10.31
2027
7.09
- -
- -
- -
- -

Quarterly Dividends Per Share

INR

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2025
- -
- -
- -
- -
1.51
2026
- -
- -
- -
- -
0.21
2027
- -
- -
- -
- -
- -

Company Description

Company Profile APIChatGPT
CEO
Aditi Kare Panandikar
Full Time Employees
6,555
Sector
Health technology
Industry
Pharmaceuticals: major
Address
Indoco House Mumbai MA India 400098
IPO Date
Jan 14, 2005
Website
indoco.com
Similar Companies
Eli Lilly and Company (NYSE:LLY)
Novo Nordisk A/S (NYSE:NVO)
Johnson & Johnson (NYSE:JNJ)
Pfizer, Inc. (NYSE:PFE)
Dr. Reddy's Laboratories Ltd. (NSE:DRREDDY)
Divi's Laboratories Limited (NSE:DIVISLAB)
Business
Indoco Remedies Limited is an integrated pharmaceutical company engaged in the research, development, manufacturing, and marketing of active pharmaceutical ingredients (APIs) and finished dosage formulations across therapeutic areas including anti-infectives, cardiovasculars, gastrointestinals, and pain management. The company offers a diverse portfolio of branded generics and prescription drugs in categories such as tablets, capsules, injectables, and ophthalmics; key brands include Citalop, Redipred, and Emcor; it also provides contract manufacturing services and exports formulations to regulated markets. Founded in 1976 and headquartered in Mumbai, India, Indoco operates manufacturing facilities in India with a presence in over 50 countries, primarily targeting emerging and developed markets in Latin America, Africa, and Southeast Asia. In recent developments, Indoco Remedies expanded its product pipeline with the launch of new formulations in dermatology and respiratory segments in 2024, alongside receiving US FDA approvals for additional generic injectables. The company strengthened its global footprint through a strategic partnership with a leading Latin American distributor for anti-infective products in early 2025 and completed a funding round to bolster R&D investments in complex generics. These initiatives reflect ongoing efforts to diversify beyond domestic sales, which account for a significant portion of revenue, while navigating regulatory enhancements at its Goa facility.